Use of preventive drugs during the last year of life in older adults with cancer or chronic progressive diseases. Issue 8 (30th March 2021)

• Record Type: Journal Article
• Authors: Bosetti, Cristina; Santucci, Claudia; Pasina, Luca; Fortino, Ida; Merlino, Luca; Corli, Oscar; Nobili, Alessandro
• Is Part Of: Pharmacoepidemiology and drug safety. Volume 30:Issue 8(2021)
• Page Start: 1057
• Page End: 1065
• Publication Date: 2021-03-30
• Subjects: deprescribing -- elderly -- end‐of‐life -- preventive drugs; Pharmacoepidemiology -- Periodicals; Chemotherapy -- Periodicals; Epidemiology -- Periodicals; 615.705
• DOI: 10.1002/pds.5223
• Languages: English
• ISSNs: 1053-8569

Abstract

Abstract: Purpose: To evaluate the prescription of preventive medications with questionable usefulness in community dwelling elderly adults with cancer or chronic progressive diseases during the last year of life. Methods: Through the utilization of the healthcare databases of the Lombardy region, Italy, we identified two retrospective cohorts of patients aged 65 years or more, who died in 2018 and had a diagnosis of either a solid cancer ( N = 19 367) or a chronic progressive disease ( N = 27 819). We estimated prescription of eight major classes of preventive drugs 1 year and 1 month before death; continuation or initiation of preventive drug use during the last month of life was also investigated. Results: Over the last year of life, in both oncologic and non‐oncologic patients, we observed a modest decrease in the prescription of blood glucose‐lowering drugs, anti‐hypertensives, lipid‐modifying agents, and bisphosphonates, and a slight increase in the prescription of vitamins, minerals, antianemic drugs, and antithrombotic agents (among oncologic patients only). One month before death, the prescription of preventive drugs was still common, particularly for anti‐hypertensives, antithrombotics, and antianemics, with more than 60% of patients continuing to be prescribed most preventive drugs and an over 10% starting a therapy with an antithrombotic, an antianemic, or a vitamin or mineral supplement. Conclusion: These findings support the need for an appropriate drug review and improvement in the quality of drug prescription for vulnerable populations at the end‐of‐life.